122 related articles for article (PubMed ID: 38299584)
1. Genetic landscape and clinical outcomes of patients with
Baranwal A; Gurney M; Basmaci R; Katamesh B; He R; Viswanatha DS; Greipp P; Foran J; Badar T; Murthy H; Yi CA; Palmer J; Mangaonkar AA; Patnaik MM; Litzow MR; Hogan WJ; Begna K; Gangat N; Tefferi A; Al-Kali A; Shah MV; Alkhateeb HB
Haematologica; 2024 Jun; 109(6):1779-1791. PubMed ID: 38299584
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
3. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
[TBL] [Abstract][Full Text] [Related]
4. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
[TBL] [Abstract][Full Text] [Related]
6. A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias.
Mavridou E; Lema Fernandez AG; Nardelli C; Pierini V; Quintini M; Arniani S; Di Giacomo D; Crescenzi B; Matteucci C; Sambani C; Mecucci C
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23235. PubMed ID: 38656651
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
8. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
9. Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
Poonsombudlert K; Mott S; Miller B; Dhakal P; Snow A; Hornberg S; Yodsuwan R; Strouse C; Shaikh H; Magalhaes-Silverman M; Sutamtewagul G
Eur J Haematol; 2024 Jul; 113(1):16-23. PubMed ID: 38511425
[TBL] [Abstract][Full Text] [Related]
10. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
11. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Montalban-Bravo G; Kanagal-Shamanna R; Class CA; Sasaki K; Ravandi F; Cortes JE; Daver N; Takahashi K; Short NJ; DiNardo CD; Jabbour E; Borthakur G; Naqvi K; Issa GC; Konopleva M; Khoury JD; Routbort M; Pierce S; Do KA; Bueso-Ramos C; Patel K; Kantarjian H; Garcia-Manero G; Kadia TM
Am J Hematol; 2020 Jun; 95(6):612-622. PubMed ID: 32112433
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
[TBL] [Abstract][Full Text] [Related]
13. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
15. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations].
Chen SF; Wang TZ; Jiang SH; Shen HJ; Xu Y; Zhou HF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):983-988. PubMed ID: 30612398
[No Abstract] [Full Text] [Related]
17. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
18. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
19. RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.
Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
Leuk Lymphoma; 2019 May; 60(5):1334-1336. PubMed ID: 30997874
[No Abstract] [Full Text] [Related]
20. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]